A randomized controlled trial of 407 older adults with obesity found that metformin added to intensive lifestyle intervention provided no additional benefit to physical function compared to lifestyle changes alone. This challenges the assumption that pharmacological intervention enhances functional outcomes when foundational behavioral change is already in place.
Key Points
- Metformin provided no additive benefit to physical function outcomes
- Intensive lifestyle intervention alone drove functional improvements
- Results suggest lifestyle prioritization over pharmacological adjuncts
Longevity Analysis
The capacity to move, maintain muscle, and perform daily activities without assistance defines functional longevity in older age. This trial demonstrates that the primary driver of functional improvement in this population is the elimination of inactivity and dietary patterns that perpetuate obesity—not pharmaceutical intervention layered on top. The finding has direct implications for resource allocation and clinical decision-making: when interference (sedentary behavior, caloric excess) is removed through structured lifestyle change, additional pharmacological tools do not compensate for incomplete adherence to behavioral fundamentals or restore additional functional gains. This reinforces a sequential rather than additive approach to optimization in aging populations.
Original published by The Lancet Healthy Longevity, by Maria Liza Duremdes Nava, Viola Viola, Marlene Aguilar, Mon S Bryant, Vijay Nambi, Reina Armamento-Villareal, Clifford Qualls, Dennis T Villareal.